Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar

📆 8/8/2567 18:31:00
📰 ForbesTech

⏱ Reading Time:
9 sec. here
11 min. at publisher
📊 Quality Score:
News: 38%
Publisher: 59%

Eli Lilly ข่าว

Novo Nordisk,Tirzepatide,Zepbound

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts’ expectations in the face ofEli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for the second quarter of 2024.

Lilly reported $3.28 earnings per share, besting expectations of $2.74, and raised the range of its annual forecast $2.05 to earnings per share between $15.10 to $15.60.

เขียนความคิดเห็น

เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว